Hovind P, Tarnow L, Oestergaard P B, Parving H H
Steno Diabetes Center, Gentofte, and Novo Nordisk, Bagsvaerd, Denmark.
Kidney Int Suppl. 2000 Apr;75:S56-61.
Growth factors have been suggested to play a role in the development and progression of diabetic nephropathy. Vascular endothelial growth factor (VEGF) is a potent cytokine family that induces angiogenesis and markedly increases endothelial permeability. The aim of the present study was to investigate plasma levels of VEGF in a large cohort of type 1 diabetic patients with diabetic nephropathy and in long-standing type 1 diabetic patients with persistent normoalbuminuria, and to evaluate VEGF as a predictor of nephropathy progression.
We measured VEGF with an enzyme-linked immunosorbent assay (ELISA) technique in 199 type 1 diabetic patients with diabetic nephropathy (122 males, age 41 +/- 10 years, diabetes duration 28 +/- 8 years), glomerular filtration rate (GFR) (median [range]) 75 [10-143] mL/min/1.73 m2, and in 188 long-standing type 1 diabetic patients with persistent normoalbuminuria (115 males, age 43 +/- 10 years, diabetes duration 27 +/- 9 years). One hundred fifty-five of the proteinuric patients were followed for at least 3 years after baseline examination with yearly GFR measurements.
Plasma levels of VEGF were significantly increased in patients with nephropathy as compared to the normoalbuminuric group; (median [range]): 45.7 [22.0-410] versus 27.1 [22.0-355] ng/L, respectively, P < 0.001. This difference was ascribed to elevated VEGF levels in nephropathic men: 51.8 [22.0-410] versus 22.0 [22.0-308] ng/L, P < 0. 001. No differences were found between women with and without nephropathy: 37.8 [22.0-325] versus 36.6 [22.0-335] ng/L, NS. In proteinuric patients with GFR above and below the median value, there was no difference in the level of VEGF, NS. Plasma VEGF was below the detection limit (22.0 ng/L) in 60 patients with nephropathy and 93 patients with normoalbuminuria, P < 0.001. The mean rate of GFR decline was 3.5 (SE: 0.4) mL/min/year, and the following baseline variables acted as predictors of progression: albuminuria, mean arterial blood pressure and male gender. Hemoglobin A1c and plasma VEGF did not act as predictors. No significant differences between patients with and without proliferative retinopathy were detected.
Our data suggest that VEGF is elevated early in the course of diabetic nephropathy in men with type 1 diabetes mellitus. Baseline albuminuria, arterial blood pressure and male gender was predictors of diabetic nephropathy progression, while plasma VEGF and Hemoglobin A1c did not contribute. The importance of VEGF in the initiation of diabetic nephropathy remains to be established.
生长因子被认为在糖尿病肾病的发生和发展中起作用。血管内皮生长因子(VEGF)是一种强大的细胞因子家族,可诱导血管生成并显著增加内皮通透性。本研究的目的是调查一大群1型糖尿病肾病患者和长期持续性正常白蛋白尿的1型糖尿病患者的血浆VEGF水平,并评估VEGF作为肾病进展预测指标的价值。
我们采用酶联免疫吸附测定(ELISA)技术,对199例1型糖尿病肾病患者(122例男性,年龄41±10岁,糖尿病病程28±8年)、肾小球滤过率(GFR)(中位数[范围])75[10 - 143]mL/min/1.73 m²,以及188例长期持续性正常白蛋白尿的1型糖尿病患者(115例男性,年龄43±10岁,糖尿病病程27±9年)进行VEGF测定。155例蛋白尿患者在基线检查后至少随访3年,每年测量GFR。
与正常白蛋白尿组相比,肾病患者的血浆VEGF水平显著升高;(中位数[范围]):分别为45.7[22.0 - 410]与27.1[22.0 - 355]ng/L,P < 0.001。这种差异归因于肾病男性患者VEGF水平升高:51.8[22.0 - 410]与22.0[22.0 - 308]ng/L相比,P < 0.001。有肾病和无肾病的女性之间未发现差异:37.8[22.0 - 325]与36.6[22.0 - 335]ng/L,无统计学意义。GFR高于和低于中位数的蛋白尿患者,VEGF水平无差异,无统计学意义。60例肾病患者和93例正常白蛋白尿患者的血浆VEGF低于检测限(22.0 ng/L),P < 0.001。GFR下降的平均速率为3.5(标准误:0.4)mL/min/年,以下基线变量可作为进展的预测指标:蛋白尿、平均动脉血压和男性性别。糖化血红蛋白A1c和血浆VEGF未起到预测指标的作用。有增殖性视网膜病变和无增殖性视网膜病变的患者之间未检测到显著差异。
我们的数据表明,1型糖尿病男性患者在糖尿病肾病病程早期VEGF升高。基线蛋白尿、动脉血压和男性性别是糖尿病肾病进展的预测指标,而血浆VEGF和糖化血红蛋白A1c并无影响。VEGF在糖尿病肾病起始阶段的重要性仍有待确定。